RT Journal Article
T1 Statins: Could an old friend help in the fight against COVID-19?
A1 Rodrigues-Diez, Raul R
A1 Tejera-Muñoz, Antonio
A1 Marquez-Exposito, Laura
A1 Rayego-Mateos, Sandra
A1 Santos Sanchez, Laura
A1 Marchant, Vanessa
A1 Tejedor Santamaria, Lucia
A1 Ramos, Adrian M
A1 Ortiz, Alberto
A1 Egido, Jesus
A1 Ruiz-Ortega, Marta
K1 Animals
K1 Betacoronavirus
K1 COVID-19
K1 Coronavirus infections
K1 Cytokines
AB The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has overwhelmed healthcare systems requiring the rapid development of treatments, at least, to reduce COVID-19 severity. Drug repurposing offers a fast track. Here, we discuss the potential beneficial effects of statins in COVID-19 patients based on evidence that they may target virus receptors, replication, degradation, and downstream responses in infected cells, addressing both basic research and epidemiological information. Briefly, statins could modulate virus entry, acting on the SARS-CoV-2 receptors, ACE2 and CD147, and/or lipid rafts engagement. Statins, by inducing autophagy activation, could regulate virus replication or degradation, exerting protective effects. The well-known anti-inflammatory properties of statins, by blocking several molecular mechanisms, including NF-κB and NLRP3 inflammasomes, could limit the "cytokine storm" in severe COVID-19 patients which is linked to fatal outcome. Finally, statin moderation of coagulation response activation may also contribute to improving COVID-19 outcomes.
PB John Wiley & Sons
YR 2020
FD 2020-06-10
LK http://hdl.handle.net/10668/15782
UL http://hdl.handle.net/10668/15782
LA en
NO Rodrigues-Diez RR, Tejera-Muñoz A, Marquez-Exposito L, Rayego-Mateos S, Santos Sanchez L, Marchant V, et al. Statins: Could an old friend help in the fight against COVID-19? Br J Pharmacol. 2020 Nov;177(21):4873-4886
DS RISalud
RD Apr 7, 2025